Rapport Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Rapport Therapeutics, Inc. (RAPP) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -1.68% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-03-10
- Rapport Therapeutics, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was -1.68%.
- Rapport Therapeutics, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month |
|---|---|
| 2024-12-31 | -1.68% 10-K · filed 2026-03-10 |
| 2023-12-31 | 0.00% 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |